Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  bevacizumab
Find trials that include:  Any drugs shown
Results 1-25 of 90 for your search:
Start Over
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-143, NCI-2014-00328, 2013-003738-34, NCT02017717
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1302.5, NCI-2016-00374, 2014-002161-30, NCT02272413
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29637, NCI-2015-01390, 2014-004684-20, NCT02420821
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: HCI55264, NCI-2012-01118, 55264, NCT01580969
Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Study of Marizomib With Bevacizumab in Subjects With WHO Grade IV Malignant Glioma Followed by a Trial of Single-Agent Marizomib
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MRZ-108, NCI-2015-00711, NCT02330562
Alectinib and Bevacizumab in Treating Patients with ALK-positive Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-055, NCI-2015-01704, NCT02521051
Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: ABI-007-PANC-009, NCI-2016-00214, NCT02620800
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-370, NCI-2016-00707, NCT02574078
Carboplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Trastuzumab or Bevacizumab before Surgery in Treating Patients with Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 to 90
Trial IDs: UCI-07-61, NCI-2010-00155, 2007-6084, NCT00618657
Valproic Acid and Radiation Therapy Followed by Maintenance Valproic Acid and Bevacizumab in Treating Young Patients With Newly Diagnosed High-Grade Gliomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: H-24549, NCI-2012-00618, NCT00879437
Hydroxychloroquine, Bevacizumab, and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 070806, NCI-2012-00527, CINJ-070806, NCT01006369
Pegylated Liposomal Doxorubicin Hydrochloride and Bevacizumab in Treating Patients with Advanced Kaposi Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0130, NCI-2013-01450, 090130, NCT00902239, P09493, NCT00923936
High-Dose Chemotherapy, Bevacizumab and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Start Over